// App-Quantinova.ai

P717 : BOSUTINIB IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA: GASTROINTESTINAL, LIVER, EFFUSION AND RENAL SAFETY CHARACTERIZATION IN THE BFORE TRIAL

Researchers

Presenter

  • Jorge E Cortes

Principal Investigators

  • Dragana Milojkovic

  • Carlo Gambacorti-Passerini

  • Valentn Garca-Gutirrez

  • Eric Leip

  • Simon Purcell

  • Andrea Viqueira

  • Tim H Brmmendorf

Medical Centers

  • Universitario Ramón y Cajal, Ramón y Cajal Health Research Institute,Madrid,Spagna

  • Pfizer SLU,Madrid,Spanje

  • Pfizer Ltd, London, United Kingdom

  • Pfizer SLU,Madrid,Испания

  • Pfizer SLU,Madrid,Spanje

  • Hospital Universitario Ramón y Cajal, Ramón y Cajal Health Research,Madrid,Spain

  • Hammersmith Hospital,London,Royaume-uni

  • Pfizer Inc., Cambridge, MA

  • Univer

  • Pfizer SLU,Madrid,Espanha

  • Georgia Cancer Center,Augusta,Verenigde Staten

  • Universitätsklinikum RWTH Aachen,Aachen,Alemania

  • University of Milano-Bicocca, Monza, Italy

  • Universitätsklinikum RWTH Aachen,Aachen,Alemania

  • Pfizer Ltd,London,Verenigd Koninkrijk

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Hammersmith Hospital,London,Regno Unito

  • University of Milano-Bicocca, Monza, Italy

  • Hammersmith Hospital,London,Storbritannien

  • Universitätsklinikum RWTH Aachen,Aachen,Allemagne

  • Hammersmith Hospital,London,Regno Unito

  • Universitario Ramón y Cajal, Ramón y Cajal Health Research Institute,Madrid,Spagna

  • Memorial Sloan Kettering Cancer Center,New York ,États-unis

  • Pfizer Ltd,London,Storbritannien

  • Georgia Cancer Center,Augusta,Stati Uniti

  • University of Milano-Bicocca, Monza, Italy

  • Pfizer Inc,Cambridge,Verenigde Staten

  • Hammersmith Hospital NHS Trust, London, United Kingdom

  • Georgia Cancer Center, Augusta, GA.

  • University of Milano-Bicocca, Monza, Italy

  • Pfizer Ltd,London,Vereinigtes Königreich

  • Universitätsklinikum RWTH Aachen,Aachen,Alemania

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Georgia Cancer Center,Augusta,États-unis

  • Epizyme, Inc.,Cambridge,Estados Unidos

  • Hammersmith Hospital,London,Vereinigtes Königreich

  • Hospital Universitario Ramón y Cajal, Ramón y Cajal Health Research,Madrid,Spain

  • Memorial Sloan Kettering Cancer Center,New York,Vereinigte Staaten

  • Memorial Sloan Kettering, NY

  • Pfizer SLU,Madrid,Spanje

  • Pfizer SLU,Madrid,Spanje

  • Universitätsklinikum RWTH Aachen,Aachen,Allemagne

  • Pfizer Ltd,London,Соединённое Королевство

  • Georgia Cancer Center,Augusta,Verenigde Staten

  • Memorial Sloan Kettering Cancer Center,New York,Vereinigte Staaten

  • Pfizer Spain, Madrid, Spain

  • University of Milano-Bicocca, Monza, Italy

  • Georgia Cancer Center,Augusta,Estados Unidos

  • Uniklinik RWTH Aachen, Aachen, Germany

  • Pfizer SLU,Madrid,Espanha

  • Pfizer Ltd,London,Royaume-uni

  • University of Milano-Bicocca, Monza, Italy

  • Universitario Ramón y Cajal, Ramón y Cajal Health Research Institute,Madrid,Spagna

  • Georgia Cancer Center,Augusta,Verenigde Staten

  • University of Milano-Bicocca,Monza,Италия

  • Hammersmith Hospital,London,Соединённое Королевство

  • Pfizer Ltd,London,Regno Unito

  • Pfizer Inc.,Cambridge,Stati Uniti

  • Pfizer Inc,Cambridge,United States

  • Pfizer Ltd,London,Regno Unito

  • Universitätsklinikum RWTH Aachen,Aachen,Германия

  • Pfizer Inc,Cambridge,Verenigde Staten

  • Memorial Sloan-Kettering Cancer Center, New York, NY, United States

  • Universitätsklinikum RWTH Aachen,Aachen,Allemagne

  • Hammersmith Hospital,London,Verenigd Koninkrijk

  • Pfizer Inc,Cambridge,États-unis

Locations

  • United States

  • United Kingdom

  • Italy

  • Spain

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Myelogenous Leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Bosutinib

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT02130557

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved